Results 271 to 280 of about 69,107 (331)

The Risk of Immune‐Mediated Skin Disease Under Dipeptidyl‐Peptidase IV Inhibitor: A Global Population‐Based Study

International Journal of Dermatology, Volume 65, Issue 2, Page 356-358, February 2026.
Noor Mruwat, Noga Givon‐Lavi, Ralf J. Ludwig, Khalaf Kridin   +3 more
wiley   +1 more source

Dipeptidyl peptidase 4 as an injury-responsive protein in the mouse sciatic nerve. [PDF]

Mol Cells
Oh Y, Cho Y.
europepmc   +1 more source

Screening and Validation: AI-Aided Discovery of Dipeptidyl Peptidase-4 Inhibitory Peptides from Hydrolyzed Rice Proteins. [PDF]

Foods
Cheng C, Cui H, Yu X, Li W.
europepmc   +1 more source

Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. [PDF]

Clin Pharmacokinet
Liu W, Yang K, Lin Y, Lu C, Liu J, Zhou H, Wang J, Zhang T, Yao L, Qi H, Zhang X, Jia R, Li X, Jing S.   +13 more
europepmc   +1 more source

Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study. [PDF]

Pharmacy (Basel)
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source

Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study. [PDF]

BMJ Open Diabetes Res Care
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA.   +16 more
europepmc   +1 more source

アログリプチンは非糖尿病被験者において食後高脂血症および食後血管内皮機能低下を改善する：予備報告 [PDF]

, 2015
Noda, Yoko
core  

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase-4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas. [PDF]

Clin Transl Sci
Chen WS, Lin TM, Chang YS, Shen YC, Hsu HC, Kuo TT, Chen SC, Chen JH, Chang CC.   +8 more
europepmc   +1 more source

Anti-Inflammatory and Survival Benefits of Dipeptidyl Peptidase 4 Inhibitors Among Patients with Gout, T2DM Patients and Chronic Kidney Disease. [PDF]

Exp Clin Endocrinol Diabetes
Shiber S, Sharabi A, Ayalon I, Naamany E, Grossman A, Molad Y.   +5 more
europepmc   +1 more source

Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Selvaraj V.
europepmc   +1 more source